RS67158B1 - 1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti - Google Patents
1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolestiInfo
- Publication number
- RS67158B1 RS67158B1 RS20250853A RSP20250853A RS67158B1 RS 67158 B1 RS67158 B1 RS 67158B1 RS 20250853 A RS20250853 A RS 20250853A RS P20250853 A RSP20250853 A RS P20250853A RS 67158 B1 RS67158 B1 RS 67158B1
- Authority
- RS
- Serbia
- Prior art keywords
- pyrazol
- derivatives
- methyl
- treatment
- neovascular diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010829.6A GB202010829D0 (en) | 2020-07-14 | 2020-07-14 | Compounds for treatment of neovascular diseases |
| PCT/GB2021/051810 WO2022013555A1 (en) | 2020-07-14 | 2021-07-14 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases |
| EP21748927.7A EP4182311B1 (en) | 2020-07-14 | 2021-07-14 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67158B1 true RS67158B1 (sr) | 2025-09-30 |
Family
ID=72139988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20250853A RS67158B1 (sr) | 2020-07-14 | 2021-07-14 | 1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12024504B2 (sr) |
| EP (1) | EP4182311B1 (sr) |
| JP (1) | JP7827690B2 (sr) |
| KR (1) | KR20230052890A (sr) |
| CN (1) | CN116075506B (sr) |
| AU (1) | AU2021309894A1 (sr) |
| BR (1) | BR112023000571A2 (sr) |
| CA (1) | CA3183466A1 (sr) |
| DK (1) | DK4182311T3 (sr) |
| ES (1) | ES3039003T3 (sr) |
| FI (1) | FI4182311T3 (sr) |
| GB (1) | GB202010829D0 (sr) |
| HR (1) | HRP20250955T1 (sr) |
| HU (1) | HUE072558T2 (sr) |
| LT (1) | LT4182311T (sr) |
| MX (1) | MX2023000570A (sr) |
| PL (1) | PL4182311T3 (sr) |
| PT (1) | PT4182311T (sr) |
| RS (1) | RS67158B1 (sr) |
| SI (1) | SI4182311T1 (sr) |
| SM (1) | SMT202500307T1 (sr) |
| WO (1) | WO2022013555A1 (sr) |
| ZA (1) | ZA202301105B (sr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| CN120917015A (zh) * | 2023-01-20 | 2025-11-07 | 元启(苏州)生物制药有限公司 | Srpk1抑制剂和使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60235761D1 (de) | 2001-08-01 | 2010-05-06 | Univ Bristol Clifton | Isoform des vegfs |
| US7569536B2 (en) | 2003-12-26 | 2009-08-04 | Masatoshi Hagiwara | Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity |
| JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| JP2012509306A (ja) | 2008-11-22 | 2012-04-19 | ザ ユニバーシティ オブ ブリストル | VEGFxxxbの新規な使用 |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| JP2016504270A (ja) | 2012-10-17 | 2016-02-12 | ザ ユニバーシティ オブ ブリストル | 眼血管形成(ocularneovasculan)を治療するのに有用な化合物 |
| GB201406956D0 (en) | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
| GB201518365D0 (en) | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
| PT3266446T (pt) * | 2016-07-07 | 2019-01-30 | Salvat Lab Sa | Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média |
| WO2019063996A1 (en) | 2017-09-27 | 2019-04-04 | Exonate Limited | INHIBITORS OF SRPK1 |
| EP3691112B1 (en) | 2017-09-29 | 2022-06-22 | Hitachi Industrial Equipment Systems Co., Ltd. | Data obtaining method, inverter, and rotating electric machine |
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
-
2020
- 2020-07-14 GB GBGB2010829.6A patent/GB202010829D0/en not_active Ceased
-
2021
- 2021-07-14 AU AU2021309894A patent/AU2021309894A1/en active Pending
- 2021-07-14 MX MX2023000570A patent/MX2023000570A/es unknown
- 2021-07-14 RS RS20250853A patent/RS67158B1/sr unknown
- 2021-07-14 CN CN202180049067.2A patent/CN116075506B/zh active Active
- 2021-07-14 WO PCT/GB2021/051810 patent/WO2022013555A1/en not_active Ceased
- 2021-07-14 SM SM20250307T patent/SMT202500307T1/it unknown
- 2021-07-14 LT LTEPPCT/GB2021/051810T patent/LT4182311T/lt unknown
- 2021-07-14 JP JP2023502982A patent/JP7827690B2/ja active Active
- 2021-07-14 EP EP21748927.7A patent/EP4182311B1/en active Active
- 2021-07-14 CA CA3183466A patent/CA3183466A1/en active Pending
- 2021-07-14 DK DK21748927.7T patent/DK4182311T3/da active
- 2021-07-14 HU HUE21748927A patent/HUE072558T2/hu unknown
- 2021-07-14 PL PL21748927.7T patent/PL4182311T3/pl unknown
- 2021-07-14 PT PT217489277T patent/PT4182311T/pt unknown
- 2021-07-14 BR BR112023000571A patent/BR112023000571A2/pt unknown
- 2021-07-14 HR HRP20250955TT patent/HRP20250955T1/hr unknown
- 2021-07-14 KR KR1020237005137A patent/KR20230052890A/ko active Pending
- 2021-07-14 FI FIEP21748927.7T patent/FI4182311T3/fi active
- 2021-07-14 SI SI202130341T patent/SI4182311T1/sl unknown
- 2021-07-14 ES ES21748927T patent/ES3039003T3/es active Active
-
2022
- 2022-08-03 US US17/817,136 patent/US12024504B2/en active Active
-
2023
- 2023-01-26 ZA ZA2023/01105A patent/ZA202301105B/en unknown
-
2024
- 2024-03-13 US US18/603,489 patent/US20240300929A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20250955T1 (hr) | 2025-10-10 |
| FI4182311T3 (fi) | 2025-08-22 |
| MX2023000570A (es) | 2023-04-19 |
| JP2023535157A (ja) | 2023-08-16 |
| US12024504B2 (en) | 2024-07-02 |
| CA3183466A1 (en) | 2022-01-20 |
| AU2021309894A1 (en) | 2023-03-09 |
| GB202010829D0 (en) | 2020-08-26 |
| EP4182311B1 (en) | 2025-06-04 |
| JP7827690B2 (ja) | 2026-03-10 |
| DK4182311T3 (da) | 2025-08-25 |
| SI4182311T1 (sl) | 2025-11-28 |
| ES3039003T3 (en) | 2025-10-16 |
| CN116075506A (zh) | 2023-05-05 |
| US20240300929A1 (en) | 2024-09-12 |
| HUE072558T2 (hu) | 2025-11-28 |
| WO2022013555A1 (en) | 2022-01-20 |
| BR112023000571A2 (pt) | 2023-01-31 |
| EP4182311A1 (en) | 2023-05-24 |
| CN116075506B (zh) | 2025-10-10 |
| ZA202301105B (en) | 2025-07-30 |
| PT4182311T (pt) | 2025-08-27 |
| LT4182311T (lt) | 2025-09-25 |
| US20220411412A1 (en) | 2022-12-29 |
| PL4182311T3 (pl) | 2025-11-12 |
| KR20230052890A (ko) | 2023-04-20 |
| SMT202500307T1 (it) | 2025-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290415A (en) | Compounds with deuterium for use in cancer treatment | |
| IL266623A (en) | A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer | |
| CA3292080A1 (en) | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| SI4340842T1 (sl) | Sotorasib za uporabo pri zdravljenju raka | |
| PT4182311T (pt) | Derivados de 1-metil-1h-pirazol-3-ilo para utilização no tratamento de doenças neovasculares | |
| PL4419526T3 (pl) | Związki heterocykliczne do stosowania w leczeniu nowotworu | |
| IL321393A (en) | CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency | |
| GB202317288D0 (en) | Pyrrolopyridone derivatives useful in the treatment of cancer | |
| IL290427A (en) | Objects and methods for administering medical agents | |
| PL3937948T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych | |
| IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
| GB202002299D0 (en) | Agents for use in the treatment of tissue damage | |
| GB202014589D0 (en) | Agents for use in the treatment of amyloidosis | |
| AU2023902805A0 (en) | Combination for use in the treatment of glioma | |
| HK40087864A (en) | Methylthioninium compounds for use in the treatment of covid-19 | |
| HK40088920A (en) | Methylthioninium compounds for use in the treatment of covid-19 | |
| CA3304484A1 (en) | Elsunersen / prax-222 for use in the treatment of scn2a-related disorders | |
| HK40087155A (en) | Composition for use in the treatment of apol1-associated disease | |
| EP4346859A4 (en) | USE OF A HISTEPIDULIN COMBINATION IN THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY | |
| GB202414668D0 (en) | Ultrasound-responsive nanoscale delivery platform for use in the treatment of biofilm-associated diseases | |
| CA3267850A1 (en) | USE OF BORATE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| GB202302121D0 (en) | Compounds for use in the treatment of schizophrenia | |
| CA3303478A1 (en) | Polypeptides for use in the treatment of glypican-3-expressing tumours | |
| HK40079284A (en) | Agents for use in the treatment of tissue damage |